Cooperative Agreement U01CA293476
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $745K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- This $642,755 Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), supports research by The Institute for Cancer Research (ICR) to investigate the role of the protein Anoctamin 6 (ANO6) in disrupting the trogocytosis process that enables cancer-associated fibroblasts to transfer lipids to pancreatic ductal adenocarcinoma (PDAC) tumor cells. The research aims to elucidate how ANO6 activity is regulated in the...
- This federal Project Grant award for $778,873, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research conducted by Cold Spring Harbor Laboratory (CSHL) to investigate the role of the enzyme SOAT1 as a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC). The key objectives of this multi-year (Jun 2025 - May 2030) research project are to use mouse and patient-derived PDAC organoid models to: 1) evaluate the...
- This $410,115 Project Grant was awarded by the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), to the University of California, San Diego (UC San Diego) to support research aimed at improving preclinical models of metastatic pancreatic cancer. The research project seeks to understand how the collagen-rich tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) drives metastasis and treatment resistance, and to develop a synthetic 3D high density...
- This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $398,398 to Cold Spring Harbor Laboratory (CSHL) to conduct research on identifying natural product-derived inhibitors of the KLK6 enzyme as a strategy to prevent the progression of preneoplastic ductal pancreatic cancer. The funding supports a multi-year project to leverage CSHL's expertise in cancer biology, genomics, and computational...
- This Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,281,520.00 in funding to The Leland Stanford Junior University to conduct research on the fundamental biological mechanisms of cancer metastasis, organ tropism, and immune evasion. The project aims to integrate genetic barcoding with single-cell profiling to uncover the key molecular drivers underlying metastatic fitness and diverse cancer cell states in pancreatic ductal...
- This Project Grant award of $616,495.00 from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), supports research to define the biological role of sulfatide in the development and progression of pancreatic cancer precursor lesions. The primary objectives are to: 1) investigate the role of sulfatide in pancreatic cancer precursor lesions, 2) test whether small molecule inhibition of sulfatide metabolism is a viable cancer interception strategy, and 3)...
- The federal Project Grant award of $268,345 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel immunotherapy for pancreatic cancer. The primary awardee, Sanford Burnham Prebys Medical Discovery Institute, will investigate the PSGL-1/VISTA axis as a potential target for boosting the anti-tumor immune response in pancreatic tumors. This 2-year project, with a start date of Mar 10, 2025 and end date of Feb 28, 2027, aims to elucidate...
- The National Institutes of Health (NIH) awarded a $1,710,000.00 Project Grant to the Salk Institute for Biological Studies in La Jolla, California under the Trans-NIH Research Support program (CFDA 93.310). The purpose of this 3-year grant, effective September 22, 2023, is to develop novel tools and model systems to track the dynamic interactions between rapid signaling, stress and metabolic responses, transcriptional changes, epigenetic modifications, and genetic alterations that contribute...
- This $667,118 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The project will focus on studying the role of key lysosomal factors, including PLBD1 and LGMN, that are essential for the survival and growth of pancreatic ductal...
- The National Cancer Institute awarded a Cooperative Agreement of $767,324 on April 1, 2025 to the Van Andel Research Institute (VAI) in Grand Rapids, Michigan under the Cancer Biology Research program (CFDA 93.396). The funding will support research to investigate how dietary caloric restriction can boost anti-tumor immunity by impacting the metabolism and function of CD8 T cells in the tumor microenvironment. The research aims to identify novel diet-regulated mechanisms linking nutrient...